(Lidocaine + prilocaine) is under clinical development by Plethora Solutions and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect (Lidocaine + prilocaine)’s likelihood of approval (LoA) and phase transition for Premature Ejaculation took place on 16 Apr 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Lidocaine + prilocaine) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

(Lidocaine + prilocaine) overview

Lidocaine and Prilocaine (Fortacin / Senstend) is a fixed dose combination. It is formulated as a spray for cutaneous and topical route of administration. It is indicated for the treatment of primary premature ejaculation in adult men and is used to treat men with primary (lifelong) premature ejaculation (when ejaculation regularly occurs before, or too early during penetration). It is under development for the treatment of premature ejaculation in adult man in the US.

Plethora Solutions overview

Plethora Solutions (Plethora), a subsidiary of Regent Pacific is a pharmaceutical company which develops and markets products for the treatment and management of urological disorders.

Quick View (Lidocaine + prilocaine) LOA Data

Report Segments
  • Innovator (Non-NME)
Drug Name
  • (Lidocaine + prilocaine)
Administration Pathway
  • Cutaneous
  • Topical
Therapeutic Areas
  • Male Health
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.